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Claudia Wickenhauser2 and Herbert Pfister1
Transgenic mice expressing early genes of the cutaneous human papillomavirus 8 (HPV8) spontaneously
develop skin papillomas, epidermal dysplasia, and squamous cell carcinoma (6%). As the HPV8 protein E2
revealed transforming capacity in vitro, we generated three epidermal specific HPV8-E2-transgenic FVB/N
mouse lines to dissect its role in tumor development. The rate of tumor formation in the three lines correlated
with the different E2-mRNA levels. More than 60% of heterozygous line 2 mice, but none of the HPV8-negative
littermates, spontaneously developed ulcerous lesions of the skin over an observation period of up to 144
weeks, beginning on average 74±22 weeks after birth. Most lesions presented infundibular hyperplasia and
acanthosis combined with low-grade dysplasia. Severe dysplasia of the epidermis occurred in 6%. Two
carcinomas revealed a sharply demarcated spindle-cell component. Only 3 weeks after a single UV irradiation,
87% of heterozygous line 2 and 36% of line 35 mice developed skin tumors. A rapidly growing invasive tumor
composed of spindle cells arose 10 weeks after irradiation of a line-35 animal. The histology of skin cancers in
HPV8-E2 mice is reminiscent of a subset of highly aggressive squamous cell carcinoma in immunosuppressed
transplant recipients with a massive spindle-cell component.
Journal of Investigative Dermatology (2008) 128, 2310–2315; doi:10.1038/jid.2008.73; published online 10 April 2008
INTRODUCTION
Human papillomaviruses (HPV) infect the epithelia of skin
and mucosa. Dependent on the virus type, they can cause
different benign and malignant tumors (Lowy and Howley,
2002). Non-melanoma skin cancer is the most common
epithelial cancer among Caucasians (Diepgen and Mahler,
2002). The major risk factors are UV radiation and exposure
to immunosuppressive drugs (Armstrong and Kricker, 2001;
Euvrard et al., 2003). A causal role of HPV in non-melanoma
skin cancer development is fully accepted in patients with
epidermodysplasia verruciformis, who develop persisting flat
warts and macular lesions usually before puberty and
squamous cell carcinoma (SCC) later in life, predominantly
on the sun-exposed areas of the skin (Jablonska and
Majewski, 1994; Orth, 2006). In contrast to the diversity of
genus b-HPV types in benign lesions, only a subset is found in
SCC, including HPV5, 8, 17, 20, and 47, which are regarded
as high-risk types. Epidemiological data also support a role of
b-HPV in the etiology of skin cancer in the general
population. b-HPV DNA can be detected in up to 50% of
skin cancers of immunocompetent people and in up to 90%
of those from immunocompromised individuals (reviewed by
Pfister, 2003; Akgu¨l et al., 2006). A significant association
was found between skin cancer and the presence of b-HPV
DNA in punch biopsies from clinically normal skin of
immunocompetent and immunosuppressed individuals
(Harwood et al., 2004). Recent seroepidemiological studies
provided some support that antibodies against the major
structural protein of HPV8 are associated with skin SCC
(Feltkamp et al., 2003; Masini et al., 2003).
To investigate the carcinogenic potential of HPV8 under
experimental conditions, we previously generated transgenic
mice with the complete early region (CER) of HPV8
(CER¼open reading frames E1/E2/E4/E6/E7) under the con-
trol of the human keratin-14 (K14) promoter. Nearly 100% of
the HPV8-CER-transgenic mice developed papillomas, par-
tially with moderate or severe dysplasia. In 6% of the
animals, SCC developed spontaneously without any previous
treatment with physical or chemical carcinogens (Schaper
et al., 2005). HPV8 is so far the only cutaneous HPV type
studied in transgenic mice, inducing skin cancer completely
on its own.
As in all papillomaviruses, the E2 protein of HPV8 is
involved in viral transcription and replication control.
However, in vitro data also point to a role of HPV8-E2 in
cell transformation. Expression in rodent fibroblasts and the
human keratinocyte line HaCaT led to anchorage-indepen-
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dent growth (Iftner et al., 1989; Fuchs et al., 1993). Therefore,
we now expressed HPV8-E2 alone in transgenic mice to
clarify its oncogenic potential.
RESULTS
Spontaneous tumor development in HPV8-E2-transgenic mice
Transgenic mice were generated, expressing HPV8-E2 under
the control of the human K14 promoter, which targets
transcription to the basal epithelial layer. Three lines were
established, two from DBA/Bl6 (line 21 and 35) and one from
FVB/N (line 2) HPV8-E2-positive founder mice. The three
lines were continuously mated with FVB/N wild-type
animals, because of their susceptibility to epidermal carci-
nogenesis (Hennings et al., 1993; Coussens et al., 1996). To
generate homozygous animals, transgene-positive littermates
were mated with each other, starting at the F1 generation of
line 2. After two generations, all offsprings were HPV8-E2-
transgenic. To confirm homozygosity, all descendants of the
F6 generation were mated with FVB/N wild-type mice and
gave rise to uniformly HPV8-E2-positive progeny.
Transgene-specific RNA was detectable in total RNA from
the epidermis of the heterozygous lines 2 and 35, but not in
any generation of mice from line 21 (Table 1). The expression
levels in lines 2 and 35 were relatively stable throughout
generations F0 to F8, and all over the life of the animals from
2 to 20 months. Homozygotes showed a twofold increased E2
expression (3.4 transcripts HPV8-E2/1 transcript b-actin)
compared with heterozygous animals of line 2 (1.7 transcripts
HPV8-E2/1 transcript b-actin), and the expression levels of
these heterozygotes were about three times as high as in the
mice of line 35 (0.6 transcripts HPV8-E2/1 transcript b-actin)
(Po0.001, Kruskal–Wallis test).
Mice from line 21 lacking detectable HPV8-E2 mRNA
expression showed no skin alterations during lifetime. All the
E2-expressing transgenics showed progressive hair loss and
shaggy fur with increasing age. At an age of 52 weeks, 8% of
the heterozygous animals (5/60) from eight generations of
line 2 and 67% of the homozygous mice (8/12) from three
generations spontaneously developed skin lesions. Within the
first year of life, homozygotes with their higher transgene
expression thus experience a 22-fold increased risk to
develop skin tumors compared with the heterozygotes
(Po0.001). Heterozygous animals of generations F0–F6 were
monitored up to 144 weeks. During this observation period,
20 more transgenics developed skin tumors. When censoring
(that is, excluding) mice that died for unknown reasons before
developing a tumor, more than 60% of the heterozygotes of
line 2 finally developed skin tumors. On average, these
tumors appeared at 74±22 weeks after birth. Two mice of
the heterozygous line 35, consisting of 20 transgenics from
six generations, spontaneously developed skin tumors at an
age of 100 and 140 weeks, respectively. The corresponding
Kaplan–Meier curves for cumulative tumor incidences
(Figure 1) show the clear-cut differences between the three
lines (Po0.0001 by log-rank test). None of the HPV8-E2-
negative control littermates of the heterozygous lines 2 and
35 developed any obvious skin alteration during lifetime.
The flat or polypous skin tumors usually developed within
or close to fuzzily demarcated ulcerous lesions, predomi-
nantly at the dorsal skin (Figure 2a). Skin tumors of 16
Table 1. Transgene expression in 16 different HPV8-
E2-transgenic mice
No.
Transgenic
mouse Generation
Age
(months)
n Transcripts HPV8-
E2/transcript b-actin1
1 Line 2 ht2 F0 20 1.85±0.17
2 Line 2 ht F1 14 1.61±0.33
3 Line 2 ht F2 11 1.45±0.09
4 Line 2 ht F3 7 1.94±0.27
5 Line 2 ht F7 16 1.97±0.45
6 Line 2 ho3 F6 12 3.00±0.10
7 Line 2 ho F6 12 3.04±0.30
8 Line 2 ho F7 9 3.88±0.46
9 Line 2 ho F7 9 3.67±0.15
10 Line 35 ht F0 20 0.68±0.03
11 Line 35 ht F1 13 0.45±0.13
12 Line 35 ht F8 2 1.05±0.21
13 Line 35 ht F8 2 0.20±0.06
14 Line 21 ht F0 20 0
15 Line 21 ht F2 13 0
16 Line 21 ht F8 8 0
HPV8, human papillomavirus 8.
1Two 4-mm skin biopsies were taken from each mouse and RNA was
isolated from the separated epidermis. HPV8-E2 mRNA levels, normal-
ized to b-actin mRNA levels, were determined in two independent assays.
The data represent the mean of four values per mouse±SD.
2Heterozygote.
3Homozygote.
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Figure 1. Kaplan–Meier curves for cumulative tumor incidence in HPV8-E2
transgenic mice. Dotted line: homozygous animals of line 2, solid line:
heterozygous animals of line 2, dashed line: line 35. Vertical bars indicate
censored mice that died for unknown reasons before developing tumor. Mice
were checked every 7 days to monitor the development of skin tumors.
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heterozygous transgenics of line 2 and 17 animals, with
uncertain zygocity resulting from breedings of transgene-
positive littermates, were histologically characterized. No
animal showed massive papillomatosis observed with the
CER transgenics (Schaper et al., 2005). Thirty (91%) of the
lesions presented a characteristic pattern of infundibular
hyperplasia (hyperplasia of hair follicle epithelium) and
acanthosis combined with hyperkeratosis and focal paraker-
atosis (Figure 2b and c). Sebaceous glands appeared enlarged
in several mice (data not shown). The dermis showed dense
inflammatory infiltrate of mixed cellularity and mild to severe
fibrosis. Most epidermal lesions exhibited low-grade epithe-
lial dysplasia as evident from disturbed epidermal stratifica-
tion and atypic keratinocytes predominantly in the basal
epithelial layers and in the follicle epithelium (Figure 2c).
Severe dysplasia of the epidermis was noted in two tumors
(6%) examined at an age of 90 and 101 weeks, respectively
(Figure 2d). Two mice of line 2, one 24 months and one 16
months old, developed fast growing, poorly differentiated,
and highly invasive SCC with more or less pronounced
spindle-cell morphology (Figure 3).
Two skin lesions of the homozygotes of line 2 were also
characterized as irregular infundibular hyperplasia and one
spontaneous tumor of line 35 was diagnosed as hyperplasia
with low-grade dysplasia (data not shown).
Skin tumor development in HPV8-E2-transgenic mice after UV
irradiation
To study the effect of UV exposure, HPV8-E2 transgenics
were irradiated with 10 J cm2 UVA and 1 J cm2 UVB at the
age of 2–13 months, a time point where the mice did not yet
show any skin lesion. Irradiation resulted in distinct
erythema, with weak inflammatory reaction, which healed
completely in transgene-negative littermates within 3 weeks
and did not lead to tumor formation. Among HPV8-E2-
positive animals, however, 87% (13/15) of the heterozygous
line 2 and 36% (4/11) of line 35 developed skin tumors
within 3 weeks (Figure 4a–c). Histologically these tumors
were similar to the spontaneously developing skin lesions in
E2 transgenic mice (data not shown).
In one 8-month-old mouse of line 35, a rapidly growing
tumor developed 10 weeks after irradiation and the mouse
was killed 3 weeks later (Figure 4d). Histological examination
showed an invasive tumor composed of spindle cells with
enlarged and pleomorphic nuclei (Figure 4e and f). Parts of
the tumor stained positive for cytokeratin-14, suggesting its
epidermal origin (spindle-cell SCC) (Figure 4g).
DISCUSSION
E2 is so far not regarded as an oncogene of HPV. On the
contrary, overexpression of genus-a HPV16- and HPV18-E2
results in cell-cycle arrest (Francis et al., 2000; Wells et al.,
2000) and apoptosis (Desaintes et al., 1999; Webster et al.,
2000) depending on the cell type and p53 status. HPV11-E2-
transgenic mice showed no histological changes in the skin
(Leykauf et al., 2008). In contrast, skin tumor formation in
HPV8-E2 mice here revealed an intrinsic oncogenic potential
of a genus-b E2 protein in vivo.
The different HPV8-E2 mRNA levels in the homozygous
and heterozygous animals of line 2 and in mice of line 35
(ratio about 6:3:1) strongly influenced the speed of tumor
development as shown by Kaplan–Meier curves. None of the
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Figure 2. Morphology and histology of spontaneous skin lesions in E2-
transgenic mice. (a) HPV8-E2-transgenic mouse of the F2 generation with
shaggy fur at the age of 23 months. An area with alopecia, ulceration, and flat
polypous tumors is seen. (b) Dorsal skin lesion with prominent infundibular
hyperplasia, acanthosis, and cutaneous fibrosis. The dermis shows dense,
chronic inflammatory infiltrate (H&E, original magnification 100). (c)
Higher magnification of a second lesion demonstrates mild epithelial
dysplasia as evident from atypic keratinocytes. Strong acanthosis and
parakeratosis. Cutaneous inflammatory infiltrate consisting of plasma cells
and lymphocytes. (d) Hyperchromatic nuclei, loss of stratification, and mitotic
figures in upper cell layers indicate severe epidermal dysplasia in this dorsal
skin tumor ((c, d) H&E, original magnification  250).
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Figure 3. Histology and immunohistochemistry of spontaneously developed
SCC. (a) Islands of cohesive, atypical squamous cells embedded in an
inflammatory background. An additional diffuse spindle-cell component is
visible. (b) The most prominent tumor component of this SCC is composed of
spindle cells. One typical squamous cell aggregate is seen. (c) Ki67 staining
demonstrates high proliferative activity of both tumor components. (d) Strong
cytokeratine-14 staining in the squamous cell aggregates and distinct staining
in a subpopulation of the atypical spindle cells (original magnification
400).
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line 21 transgenics, with no detectable HPV8-E2 mRNA
expression, showed any skin tumor formation during the
whole observation period. It is reassuring that skin tumor-
igenesis roughly correlated with basal E2 expression. As
expected for an integrated transgene and already shown for
HPV8-CER mice (Schaper et al., 2005), E2 was continuously
expressed in the tumors (data not shown). A quantitative
comparison is not meaningful because of the varying ratios of
K14 promoter-permissive cells in tumors and normal skin.
Tumor development in the heterozygous transgenics of
line 2 took about 1.3 and 2.8 times as long as in the HPV8-
CER-FVB/N lines 85 and 9, respectively (Schaper et al.,
2005). Macroscopically, E2 mouse tumors were rather flat
and did not show marked papillomatosis with massive
thickening of the epidermis and prominent hyperkeratosis
of HPV8-CER-mouse tumors. Similar to HPV8-CER trans-
genics, a severe dysplasia of the epidermis was observed in
6% of the tumors. Two spontaneous SCCs were diagnosed in
E2 mice, which showed remarkable, previously unidentified,
spindle-cell component.
The vast majority of HPV8-E2 skin tumors were associated
with obvious skin ulcerations and the ulcers seemed to
precede tumor formation. The skin ulcerations may be
triggered by the E2 expression in basal epidermal keratino-
cytes. The interaction of E2 with cellular transcription factors
such as C/EBP and the activation of the C/EBPb-responsive
involucrin gene promoter strongly suggests that E2 contri-
butes to keratinocyte differentiation (Hadaschik et al., 2003).
In the context of the CER of HPV8, this differentiation-
stimulating E2 effect is balanced by the effects of the
oncoproteins E6 and E7, which transiently suppress kerati-
nocyte differentiation. This is consistent with the natural
course of HPV infection in which E7-mediated induction of
proliferation occurs in the first suprabasal layers to guarantee
viral DNA replication, and E2 triggers induction of keratino-
cyte differentiation at later stages to guarantee virus matura-
tion. In our model, E2 is expressed alone in the basal,
proliferative, epidermal compartment, and may lead to
premature keratinocyte differentiation, reduction of the
proliferative pool of keratinocytes, and thinning of the
epidermis in older transgenic mice. Such a scenario would
be in line with our observation that E2-transgenic mice older
than 16 months histologically exhibit areas of extremely thin
epidermis, with absence of a clearly distinguishable
basal keratinocyte layer (data not shown). It is well
imaginable that banal trauma in such mice leads to skin
ulcerations, which cannot be repaired efficiently due to the
lack of proliferation-competent basal keratinocytes. Chronic
skin inflammation and/or a frustrane wound-healing reaction
may then condition the tissue for tumor formation.
This would be consistent with clinical observations showing
that SCC in man can be associated with chronic, non-healing
skin wounds.
Although chronic skin inflammation has been brought into
connection with skin tumorigenesis (van Hogerlinden et al.,
2004), inflammation is unlikely to be the only reason for
tumor development in our E2-transgenic mice. The tumors
frequently showed signs of dysplasia in regions where the
epithelium did not directly border ulcerous skin defects.
We have shown previously that overexpression of the full-
length HPV8-E2 in primary human foreskin keratinocytes
does not primarily induce apoptosis, in contrast to HPV18-E2
(Oldak et al., 2004). We also stressed before that skin
carcinogenesis in HPV8-CER mice takes place in spite of
large amounts of E2 mRNA, indicating that E2 has at least no
inhibitory effect on tumor progression (Schaper et al., 2005).
Our study suggests that HPV8-E2 even actively promotes
transformation. Nevertheless, the lack of proapoptotic activi-
ties is probably an important prerequisite for manifestation of
the oncogenic functions of HPV8-E2.
A single solar-simulated irradiation with UVA and UVB,
which did not cause skin tumors in non-transgenic mice, was
a d
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Figure 4. Tumor development in HPV8-E2-transgenic mice (FVB/N) caused by UV irradiation with 10 J cm2 UVA and 1 J cm2 UVB. (a) Negative
littermate 8 weeks after the UV treatment without any skin alterations. (b, c) HPV8-E2-positive mice of the F4 generation of line 2, with skin lesions growing 3 (b)
and 8 weeks (c), respectively, after UV irradiation. (d) 1.5 20.7 cm exophytic, rapidly growing tumor, which developed within 3 weeks in the area
of a preexisting, UV-induced ulcus. (e) Histology reveals epidermis with superficial erosion and disturbed stratification, beneath sharply demarcated
spindle-cell tumor with strong cytological atypia and atypical mitosis (original magnification  250). (f) Invasive growth pattern is indicated by infiltration
of striated muscles (original magnification  650). (g) A subpopulation of tumor cells reveals cytokeratin-14 staining (original magnification  400).
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sufficient to induce papilloma growth within 3 weeks in 87%
of line 2 and 36% of line 35 mice. Tumor growth thus started
much faster and more frequently than in non-irradiated
transgenics (see Figure 1). It is known that UVB activates the
K14 promoter (Bernerd et al., 2001), which might have led to
an upregulation of E2 expression levels in K14 promoter-
permissive keratinocytes, resulting in faster accumulation of
E2 effects. E2 might also contribute to tumor progression by
interfering with the UV-damage response pathway and
impeding cell-cycle arrest and apoptosis. This hypothesis is
supported by the fact that E2 of HPV8 and/or other
papillomaviruses interacts with several cellular proteins
involved in DNA-damage response, like p53 (Massimi
et al., 1999; Akgu¨l et al., 2003), TopBP1 (Boner et al.,
2002), and PARP (Lee et al., 2002).
In humans, HPV8-E2 is under the control of its natural
promoter and certainly less abundantly expressed in basal
and suprabasal keratinocyte layers than in the mice under
K14 promoter control. However, it is generally accepted that
HPV-E2 together with E1 is expressed in proliferation-
competent basal cells of the epithelium in order to maintain
viral DNA as an episome (Frattini and Laimins, 1994) and to
tether viral genomes to mitotic chromosomes for segregation
during cell division (You et al., 2004). Even a low-level
expression of E2 in these cells, particularly relevant to
oncogenesis, may significantly contribute to skin carcinogen-
esis in cases of long persistence over many years.
All three SCCs that developed in HPV8-E2-transgenic mice
either spontaneously or upon UV irradiation showed, apart
from their epithelial parts, an unusually high proportion of
spindle cells. In view of this infrequent histological feature, it
is highly interesting to note that a spindle-cell component
was present in almost 20% of skin SCCs from immunosup-
pressed organ transplant recipients. In five of 60 cases, more
than 90% of the tumor mass was composed of spindle cells
(Harwood et al., 2006). All five human spindle-cell SCCs
presented as ulcerated nodules; two were highly aggressive
with rapid growth, and one progressed to metastatic disease.
We have previously described a threefold higher prevalence
of HPV8-specific antibodies in renal transplant recipients
compared with the general population (Stark et al., 1998),
pointing to an activated replication of HPV8 in immuno-
compromised patients. It is tempting to speculate that the
development of SCC of the spindle-cell type could specifi-
cally be stimulated by HPV8-E2.
MATERIALS AND METHODS
Construction and preparation of the transgene
The genomic region of HPV8 spanning the E2 reading frame was
amplified with specific PCR primers (fw, 50-GGATCCGATCAAGAA
GACGAGGGCGAAC-30; bw, 50-GGATCCGCATGCTGTGTTAG
TAGCAAGGCAGCGTTAG-30). The amplimers were digested with
BamHI and inserted into the BamHI restriction site of the
K14CreERtam plasmid (Vasioukhin et al., 1999), located between
the sequence of the second intron of the rabbit b-globin gene and the
K14 polyadenylation site. The resultant recombinant plasmid, K14-
HPV8-E2, was sequenced to verify the sense orientation of the HPV8
insert and its intact state. This plasmid was then digested with SacI
and HindIII, and the transgene-containing fragment was purified via
agarose gel electrophoresis and Millipore membrane filtration.
Generation of HPV8-E2-transgenic mice
The linearized transgene was microinjected into the pronucleus of
fertilized mouse oocytes of the DBA/Bl6 and the FVB/N background
(Harlan, Borchen, Germany), which were implanted into pseudo-
pregnant surrogate mothers (Hammes and Schedl, 2000), to produce
putative founder mice expressing the K14-HPV8-E2 transgene.
Founders bearing the transgene were crossed with FVB/N wild-type
mice. To establish homozygous animals, transgene-positive litter-
mates were mated with each other. To confirm homozygosity, all
descendants were crossed with FVB/N wild-type animals. The
district government Cologne approved the generation of the
transgenic mice (50.203.2-K 29, 33/01) and the UV irradiation
experiments (50.203.2-K 29, 23/04).
Characterization of HPV8-E2 transgenics
All mice were checked every 7 days to monitor development of skin
alterations. After documentation of lesions, an autopsy was
performed together with preparation of whole-skin tumor. One part
of the tumor tissue was snap frozen in liquid nitrogen and stored at
80 1C. The other half was fixed in 4% buffered formalin and
embedded in paraffin. Sections were stained with hematoxylin/eosin
for histological analysis.
Immunohistochemical staining
Endogenous peroxidase and non-specific binding were blocked by
incubating 3-mm sections of formalin-fixed tissue in 0.3% hydrogen
peroxide solution for 20minutes and in normal goat serum for
30minutes. Incubation with antiserum against mouse K14 (MK14
(AF64); Covance, Berkeley, CA) diluted 1:1000 and Ki67 (Tec-3;
Dako, Glostrup, Denmark) diluted 1:50 in Zymed Antibody Diluent
(Zytomed, San Francisco, CA) was performed at 4 1C for overnight.
The slides were then incubated with the secondary biotinylated
antibody for 30minutes at room temperature. The antibody complex
horseradish peroxidase (Vectastain Elite ABC kit; Vector Labora-
tories, Burlingame, CA) was developed with 3-amino-9-ethylcarba-
zole (AEC) and substrate chromogen (Dako). Finally, sections were
counterstained with hematoxylin and mounted with glycerin
gelatine. The specificity of the staining was checked by omitting
incubation with the primary antibody.
UV irradiation
UV irradiation was performed with UV lamp UV 801 equipped with
eight PUVA bulbs (UVA, 320–400nm) and four UV21 bulbs (UVB,
280–360nm, with a peak at about 314nm) (Waldmann, Villingen-
Schwenningen, Germany). The minimal erythemal dose for UVB was
determined at 0.5 and 10 J cm2 for UVA. The energy output of the
UV-device as measured at the level of the skin surface using a UV-
radiometer Variocontrol (Waldmann) was 1.41mWcm2 for the UVB
portion and 6.34mWcm2 for the UVA portion. The administered
doses were one minimal erythemal dose for UVA and two minimal
erythemal doses for UVB. Prior to UV radiation, mice were anesthetized
with ketamine hydrochloride (Sigma, Deisenhofen, Germany) and
xylazine hydrochloride and shaved with an electric shaver on their
back. Mice were irradiated on 4-cm2 areas, whereby the remaining skin
was covered with an UV radiation-impermeable aluminum foil.
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Quantification of HPV8-E2 mRNA
The mice were narcotized and shaved to obtain four 4-mm punch
biopsies, which were stored in RNAlater (Qiagen, Hilden, Germany)
to conserve the total amount of RNA. After incubation with
thermolysin (Protease Type X; Sigma), the epidermis was separated
from the dermis and complete epidermal RNA was isolated with the
tissue-specific protocol of the Qiagen RNA Mini kit (Qiagen). A 2-mg
weight of RNA was reverse transcribed with the cDNA Synthesis kit
(Fermentas, St Leon-Rot, Germany). cDNA levels were determined,
as previously described (Schaper et al., 2005), by real-time PCR with
SybrGreen (Invitrogen, Karlsruhe, Germany).
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